From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis

by Bersanelli, Melissa, Buti, Sebastiano
Published in World J Clin Oncol (2017)

Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential

by Bersanelli, Melissa, Buti, Sebastiano
Published in Ther Adv Med Oncol (2017)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date

by Bersanelli, Melissa, Leonardi, Francesco, Buti, Sebastiano
Published in Cancer Manag Res (2018)

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a “transcriptomic compass”?

by Bersanelli, Melissa, Cortellini, Alessio, Buti, Sebastiano
Published in Ann Transl Med (2019)

The interplay between cholesterol (and other metabolic conditions) and immune-checkpoint immunotherapy: shifting the concept from the “inflamed tumor” to the “inflamed patient”...

by Bersanelli, Melissa, Cortellini, Alessio, Buti, Sebastiano
Published in Hum Vaccin Immunother (2021)

Systemic adjuvant therapies in renal cell carcinoma

by Buti, Sebastiano, Bersanelli, Melissa, Donini, Maddalena, Ardizzoni, Andrea
Published in Oncol Rev (2012)

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report

by Bordi, Paola, Tiseo, Marcello, Baldari, Giorgio, Buti, Sebastiano
Published in BMC Cancer (2016)

Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy

by Buti, Sebastiano, Leonetti, Alessandro, Dallatomasina, Alice, Bersanelli, Melissa
Published in Core Evid (2016)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma

by Leonetti, Alessandro, Leonardi, Francesco, Bersanelli, Melissa, Buti, Sebastiano
Published in Ther Clin Risk Manag (2017)

Family history of cancer and DNA damage response genes: Two sides of the same coin?

by Cortellini, Alessio, Bersanelli, Melissa, Ficorella, Corrado, Buti, Sebastiano
Published in Thorac Cancer (2018)

Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives

by Facchinetti, Francesco, Bordi, Paola, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello
Published in Drug Des Devel Ther (2018)

Pathological nodal staging score for renal cell carcinoma: how to build reliable therapeutic choices basing on assumptions

by Bersanelli, Melissa, Buti, Sebastiano, Santoni, Matteo, Ziglioli, Francesco, Maestroni, Umberto
Published in Ann Transl Med (2019)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review

by Bersanelli, Melissa, Brunelli, Matteo, Gnetti, Letizia, Maestroni, Umberto, Buti, Sebastiano
Published in Ther Adv Med Oncol (2020)

Role of stereotactic body radiation therapy for the management of renal cell carcinoma: tailoring treatment in the era of the “embarrassment of riches”

by Buti, Sebastiano, Leonetti, Alessandro, Lattanzi, Elisabetta, D’Abbiero, Nunziata, Bersanelli, Melissa
Published in Ann Transl Med (2019)

Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

by Buti, Sebastiano, Donini, Maddalena, Bersanelli, Melissa, Gattara, Alessia, Leonardi, Francesco, Passalacqua, Rodolfo
Published in Drugs R D (2017)

Correction to: Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study

by Buti, Sebastiano, Donini, Maddalena, Bersanelli, Melissa, Gattara, Alessia, Leonardi, Francesco, Passalacqua, Rodolfo
Published in Drugs R D (2018)

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

by Bersanelli, Melissa, Buti, Sebastiano, Camisa, Roberta, Brighenti, Matteo, Lazzarelli, Silvia, Mazza, Giancarlo, Passalacqua, Rodolfo
Published in Cancers (Basel) (2014)

Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism?

by Roviello, Giandomenico, Buti, Sebastiano, Cattrini, Carlo, Mennitto, Alessia, Messina, Carlo, Airoldi, Chiara, Vannini, Gianmarco, Bersanelli, Melissa
Published in Ther Adv Urol (2021)

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients

by Bersanelli, Melissa, Giannarelli, Diana, Leonetti, Alessandro, Buti, Sebastiano, Tiseo, Marcello, Nouvenne, Antonio, Ticinesi, Andrea, Meschi, Tiziana, Procopio, Giuseppe, Danielli, Riccardo
Published in Future Oncol (2021)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors

by Dall’Olio, Filippo G., Abbati, Francesca, Facchinetti, Francesco, Massucci, Maria, Melotti, Barbara, Squadrilli, Anna, Buti, Sebastiano, Formica, Francesca, Tiseo, Marcello, Ardizzoni, Andrea
Published in Ther Adv Med Oncol (2020)